Guardian Pharmacy Services (NYSE:GRDN) vs. SCYNEXIS (NASDAQ:SCYX) Critical Analysis

Guardian Pharmacy Services (NYSE:GRDN) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Profitability

This table compares Guardian Pharmacy Services and SCYNEXIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guardian Pharmacy Services	3.64%	30.72%	15.99%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Risk & Volatility

Guardian Pharmacy Services has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Institutional & Insider Ownership

54.4% of SCYNEXIS shares are owned by institutional investors. 33.0% of Guardian Pharmacy Services shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Guardian Pharmacy Services and SCYNEXIS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardian Pharmacy Services	$1.46 billion	1.34	$49.22 million	$0.83	47.10
SCYNEXIS	$20.60 million	1.86	-$8.61 million	($3.84)	-1.00

Guardian Pharmacy Services has higher revenue and earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Guardian Pharmacy Services and SCYNEXIS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardian Pharmacy Services	0	2	7	0	2.78
SCYNEXIS	1	0	1	0	2.00

Guardian Pharmacy Services presently has a consensus price target of $42.83, indicating a potential upside of 9.56%. SCYNEXIS has a consensus price target of $24.00, indicating a potential upside of 523.38%. Given SCYNEXIS’s higher possible upside, analysts clearly believe SCYNEXIS is more favorable than Guardian Pharmacy Services.

Summary

Guardian Pharmacy Services beats SCYNEXIS on 10 of the 14 factors compared between the two stocks.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.